Protective Function of Mitogen‐Activated Protein Kinase Phosphatase 5 in Aging‐ and Diet‐Induced Hepatic Steatosis and Steatohepatitis

Peng Tang, Heng Boon Low, Chin Wen Png, Federico Torta, Jaspal Kaur Kumar, Hwee Ying Lim, Yi Zhou, Henry Yang, Veronique Angeli, Asim Shabbir, E. Shyong Tai, Richard A. Flavell, Chen Dong, Markus R. Wenk, Dan Yock Yang, Yongliang Zhang – 1 March 2019 – Nonalcoholic fatty liver disease is currently the most common liver disease and is a leading cause of liver‐related morbidity and mortality. However, its pathogenesis remains largely unclear.

Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Steven M. Kawut, Susan S. Ellenberg, Michael J. Krowka, David Goldberg, Hugo Vargas, David Koch, Tiffany Sharkoski, Nadine Al‐Naamani, Alyson Fox, Robert Brown, Joshua Levitsky, Jae K. Oh, Grace Lin, Nianfu Song, Carl Mottram, Margaret F. Doyle, David E. Kaplan, Samir Gupta, Michael B. Fallon – 28 February 2019 – The tyrosine kinase inhibitor sorafenib improves hepatopulmonary syndrome (HPS) in an experimental model. However, the efficacy and adverse effect profile in patients with HPS are unknown.

Reply

Jaclyn LoPiccolo, Michael I. Brener, Kiyoko Oshima, Evan J. Lipson, James P. Hamilton – 28 February 2019

Subscribe to